Last Posted: Jun-24-2019 11AM
Last Posted: Jun 24, 2019
- [III. Hereditary Breast and/or Ovarian Cancer Syndrome].
Sugitani Ikuko et al. Gan to kagaku ryoho. Cancer & chemotherapy 2018 Dec 45(12) 1720-1724 - Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
Grinstein Olga et al. Surgical oncology 2019 Jun 29126-133 - Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis Georgios N et al. BMC cancer 2019 Jun 19(1) 535 - Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
Salyer Chelsea et al. Gynecologic oncology 2019 May - Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
Samadder N Jewel et al. Mayo Clinic proceedings 2019 Jun 94(6) 1084-1098 - High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
Chen Justin et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Jun - Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
Trivedi Meghna S et al. Public health genomics 2019 Jun 1-11 - Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
Cao Wen-Ming et al. BMC cancer 2019 Jun 19(1) 551 - Genetic testing and eHealth usage among Deaf women.
Kushalnagar Poorna et al. Journal of genetic counseling 2019 Jun - Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Zoe et al. JAMA network open 2019 May 2(5) e194428
.jpeg)
No hay comentarios:
Publicar un comentario